Two reports underline how real-world biology and adverse-event tracking are shaping modern oncology decision-making. One case analysis describes how loneliness and complex health trajectories can co-travel with multimorbidity in aging populations—useful background for survivorship planning when treatment burdens are sustained over time. Separately, broader cancer care standards are scrutinized: a maturity model finds gaps in survivorship care standards at cancer centers, highlighting that structured follow-up is not consistently delivered even after active treatment ends. For biotech and healthcare stakeholders, these gaps affect how endpoints are measured, how long-term safety is monitored, and how adherence is supported. Together, the findings point to a more operational definition of “success,” extending beyond tumor response into coordinated survivorship execution and monitoring of patient wellbeing.